community download

Presentation: Tina Washington

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Tina Washington, Senior Clinical Trial Manager, sanofi Pasteur joined us the World Vaccine Congress Washington 2012 to review the innovative strategies and methods being employed in the implementation of 2 large Fluzone HD trials. The background of the Fluzone HD Program can be summed up as follows:

• High dose trivalent inactivated influenza vaccine
• Phase IIIb efficacy trial for a post-marketing commitment to the accelerated approval of Fluzone High-Dose
• FIM07- 3yrs, 33k subjects
o 1 of 3 years completed
o CBER agreed to postpone year 2 of study due to low attack rate in year 1 and pending post pandemic year
• FIM12- 2 yrs, 30k subjects
o Broader illness definition to trigger an increase in NP swab rate

The main aim of the FIM trial methodology philosophy is to make sure everyone involved knows that this is not a typical flu trial. The key to success has been identified as the operational advisory panel. The panel was a key contributor to the success of the trial. Find out how by downloading the full presentation here >

Tell us what you think by commenting in the space provided below.